Wedbush analyst David Nierengarten raised the firm’s price target on AnaptysBio to $20 from $18 and keeps a Neutral rating on the shares following the Q3 results. AnaptysBio continues to make progress on its pipeline targeting systemic autoimmune and inflammatory diseases, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANAB:
- AnaptysBio reports Q3 collaboration revenue $3.3M vs. $1.3M last year
- Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
- Anaptys Announces Participation in November Investor Conferences
- Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
- Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25